CompletedPhase 4ACTRN12610000695000

Parathyroid gland size and responsiveness to cinacalcet therapy in hemodialysis patients with secondary hyperparathyroidism

Sponsor

Kobe University School of Medicine

Enrollment

75 participants

Start Date

Jan 1, 2008

Study Type

Interventional

Conditions

Hemodialysis patients with secondary hyperparathyroidism

Summary

The purpose of this study was twofold: (1) to elucidate whether parathyroid gland size could be used as an indicator of response to cinacalcet therapy and (2) to examine whether cinacalcet reduces parathyroid gland volume in patients with secondary hyperparathyroidism.

Eligibility

Sex: Both males and femalesMin Age: 18 Yearss

Plain Language Summary

Simplified for easier understanding

This study examines whether the size of your parathyroid glands affects how well you respond to cinacalcet, a medication for overactive parathyroid glands in people on dialysis. You must be 18 or older, on dialysis for at least 16 weeks, and have elevated parathyroid hormone levels. People who have had parathyroid surgery or an unstable medical condition in the last 30 days cannot join.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

Cinacalcet hydrochloride, 25 mg once daily, given orally, for 52 weeks. The doses were increased to the next sequential daily dose in the series 25, 50, 75, and 100 mg after at least a 3-week interval if their intact parathyroid hormone was >180 pg/ml at the previous study visit, unless serum calcium was <8.4 mg/dl.

Locations(1)

Japan

View Full Details on ANZCTR

For the most up-to-date information, visit the official listing.

Visit

ACTRN12610000695000